Logomix Inc is a synthetic biology company specializing in mammalian cellular genome engineering. Its proprietary platform, Geno-Writing™, enables large-scale genetic modifications, allowing for the creation of versatile human cells and microbes tailored for drug development and cell and gene therapy. Unlike many competitors focused solely on optimizing gene clusters, Logomix addresses the complexities of mammalian genomes, providing innovative solutions for various applications in human health, biomaterials, and agriculture. The company actively collaborates with partners, maintaining 11 ongoing research partnerships, and is particularly seeking industry collaborators to tackle unmet needs in neurodegenerative diseases. Through its advanced technology, Logomix aims to reshape the landscape of genome engineering and facilitate groundbreaking advancements in regenerative medicine and cell therapy.
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.
Carbon Biosciences develops genetic medicines for the treatment of devastating diseases. They develop their vector using industrial-scale viral production platforms and can be used to deliver a wide-range of therapeutic modalities.
Modulus Discovery is a private Tokyo-based preclinical stage drug discovery company focused on rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The international team at Modulus is comprised of drug design and disease biology experts with previous R&D experience at global pharmaceutical, biotechnology , and computational technology firms.
Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.
TAGCyx Biotechnologies is a Tokyo-based company founded in 2007 that specializes in the development of novel nucleic acid-based drugs for therapeutic purposes. The company has created the Xenoligo platform, which employs genetic alphabet expansion through unnatural base pairs to produce customized nucleic acids tailored for various therapeutic applications. This proprietary technology enables the discovery of highly functional oligonucleotide drugs, positioning TAGCyx at the forefront of innovative solutions in the biotechnology sector.
VividQ is a deep tech software company with world-leading expertise in 3D holography, the next-generation display technology. It offers the world’s first complete software platform, powering full 3D holographic display on standard computing power. The company's software brings real-time computer-generated holography (CGH) to everyday applications such as AR/VR headsets and smart glasses, automotive head-up displays, and consumer electronics.
The company was founded in February 2017 in Cambridge by a technical team of Ph.D. graduates from Oxford, St Andrews, and Cambridge itself. Following the development of Core - VividQ’s proprietary software engine - the company has reinforced its market-leading position in the AR/VR and digital display industry. VividQ collaborates with chipmakers, display nad consumer electronics manufacturers around the world, making holography a viable commercial display solution for the first time.
TELEXISTENCE inc. provides robotics and cloud data services. It develops a production prototype, MODEL H, that uses remote control technologies utilizing the Telexistence technology, virtual reality (VR), telecommunication, cloud and haptics. The company was founded in 2017 and is based in Minato-ku, Japan.
Heartseed Inc., founded in 2015 and based in Tokyo, Japan, focuses on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company aims to advance the clinical application of regenerative medicine specifically for treating heart disease. Heartseed is dedicated to creating cardiomyocyte replacement therapies derived from iPS cells to address advanced heart failure, aspiring to transform the treatment landscape for patients suffering from this condition.
LiberoThera Co., Ltd. engages in the discovery of drugs targeting on membrane proteins for the medical care industry. It also offers drug discovery services. The company was founded in 2018 and is based in Tokyo, Japan.
Sonas Inc., headquartered in Tokyo, Japan, specializes in the planning, design, manufacturing, and sale of hardware and software solutions focused on sensing and measurement technologies. The company is developing "UNISONet," a wireless sensing technology aimed at enhancing the Internet of Things (IoT) infrastructure. This innovative solution seeks to improve upon existing mesh network technologies by integrating features such as power saving, multihop communication, time synchronization, lossless data collection, high-speed acquisition, and low-latency bidirectional communication, all simultaneously. By prioritizing high-quality wireless sensing, Sonas aims to establish itself as a fundamental component of modern societal infrastructure.
RIN Institute Inc. engages in research and development of medicines and external diagnostic drugs based on monoclonal antibodies. The company was founded in 2016 and is based in Tokyo, Japan.
Urban X Technologies' service supports inspection of the road conditions. AI technology-based inspection enables to detect the damage of the road and send an alert to investigator. This gives more efficient way of inspection rather than relying on visual confirmation by an investigator for any damages on the road.
Urban X Technologies' service supports inspection of the road conditions. AI technology-based inspection enables to detect the damage of the road and send an alert to investigator. This gives more efficient way of inspection rather than relying on visual confirmation by an investigator for any damages on the road.
BionicM is a Tokyo-based company that specializes in the research, development, and commercialization of advanced mobility devices that integrate robotics with human anatomy. The company focuses on creating high-performance robotic prosthetic devices, specifically ankle-foot and knee joints, aimed at enhancing mobility for individuals with disabilities. BionicM began its innovative research in 2015 at the University of Tokyo's Information Systems Engineering Laboratory under the guidance of Professor Inaba, leveraging cutting-edge robotics technology. In 2016, it was selected by the Japan Science and Technology Agency for a program designed to foster startups emerging from advanced research, and in 2018, BionicM was officially established as a joint-stock company.
Adriakaim Inc. is a Tokyo-based company established in 2018 that specializes in the research, design, development, manufacture, and sale of medical and health-related equipment. In addition to its product offerings, the company provides consulting services focused on management and technology strategy within the medical device sector, as well as support for research and development projects. Adriakaim aims to enhance healthcare solutions through its innovative approach to medical device technology.
Spectronics is a development of new technologies and new applications to bring about innovation, focusing on the future of laser technology.
FIMECS is a protein degradation technology-based drug discovery biotech focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The human body is comprised of at least 18,097 proteins.It has been revealed that 1,500 of them are related to certain diseases, nevertheless only about 300 proteins have been regarded as druggable targets by small molecule drug discovery and all the rest have been undruggable.
Onedot Inc. develops and operates an online platform that offers easy-to-understand baby food recipes and one-minute videos relating to childcare. It offers childcare know-how, baby food recipe, handmade goods making method, introduction of childcare products, and educational toys. The company was founded in 2016 and is based in Tokyo, Japan.
Modulus Discovery is a private Tokyo-based preclinical stage drug discovery company focused on rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The international team at Modulus is comprised of drug design and disease biology experts with previous R&D experience at global pharmaceutical, biotechnology , and computational technology firms.
TAGCyx Biotechnologies is a Tokyo-based company founded in 2007 that specializes in the development of novel nucleic acid-based drugs for therapeutic purposes. The company has created the Xenoligo platform, which employs genetic alphabet expansion through unnatural base pairs to produce customized nucleic acids tailored for various therapeutic applications. This proprietary technology enables the discovery of highly functional oligonucleotide drugs, positioning TAGCyx at the forefront of innovative solutions in the biotechnology sector.
Aidemy Inc. provides online artificial intelligence (AI) programing services for individuals to learn AI technology and a Software as a service product for companies to manipulate AI technology using their accumulated data on their own. The company’s platform is used to learn about block chain through practical applications, such as mining, adding transactions, and consensus algorithms. Its solutions are used by corporations primarily in the manufacturing industry, such as companies listed on the First Section of the Tokyo Stock Exchange and small companies and university laboratories. The company was founded in 2014 and is based in Tokyo, Japan.
AccuRna, Inc. is a biotechnology company established in 2015 and headquartered in Tokyo, Japan. The company focuses on researching and developing nucleic acid-based drugs, employing advanced drug delivery system technologies. AccuRna aims to foster therapeutic innovation by providing effective treatments for refractory diseases that currently lack cures. Through its robust platform, the company aspires to deliver safe and efficient nucleic acid therapies, ultimately striving to offer radical cures to patients suffering from challenging medical conditions worldwide.
WealthNavi Inc. develops and delivers an online asset management and risk management platform. Its cloud-based platform provides robo advisory services that enable users to locate diversified investments internationally. The company was founded in 2015 and is headquartered in Tokyo, Japan.
Synspective Inc. provides data by utilizing and integrating data from synthetic aperture radar satellite constellations, big data, and machine learning. It serves urban design, infrastructure, energy, insurance, and finance markets. The company is based in Tokyo, Japan.
Connected Robotics Inc, founded in 2014 and based in Koganei-shi, Japan, specializes in designing and manufacturing robotic arms tailored for the food service industry. Their flagship product, OctoChef, addresses labor shortages in restaurants by utilizing advanced artificial intelligence and deep learning technologies to streamline cooking processes. The company's solutions are aimed at a diverse clientele, including individual restaurants, shopping malls, service areas, amusement centers, and large-scale events. By enhancing kitchen efficiency and enabling the provision of healthy meals, Connected Robotics aims to improve the work environment for staff and contribute positively to society.
Astroscale Holdings Inc. engages in the development of technologies to remove orbital debris. It offers services, such as end-of-life service by Astroscale (ELSA), a spacecraft retrieval service for satellite operators; and active debris removal (ADR). It also designs and manufactures the lunar dream capsule which gives people a chance to send their names into space. Astroscale Holdings Inc. was founded in 2019 and is headquartered in Tokyo, Japan with additional offices in Harwell, United Kingdom; and Singapore.
EdiGENE Inc. is a biotechnology company that specializes in developing therapeutics for genetic disorders. Founded in 2016 and headquartered in Tokyo, Japan, with additional offices in Cambridge, Massachusetts, the company leverages its proprietary technologies, including clustered regularly interspaced short palindromic repeats (CRISPR) and guide nucleotide directed modulation (GNDM), to create innovative treatments. EdiGENE's focus is on addressing unmet medical needs through its advanced therapeutic solutions, supported by a strong foundation of intellectual property licensed from the University of Tokyo.
QD Laser, Inc. is a manufacturer of quantum dot semiconductor lasers and wafers, utilizing GaAs substrate for various applications in communications and industry. The company produces a range of products, including picosecond short-pulse DFB lasers for precision processing, current injection-type lasers in green, yellow-green, and orange for biological sciences, and quantum dot laser arrays for silicon optical circuits. Additionally, it offers broadband gain chips for ophthalmic testing equipment and retinal imaging laser eyewear. QD Laser's technology is applied in areas such as silicon photonics, sensing, and precision machining. The company serves a diverse clientele across telecommunications, manufacturing, medicine, and consumer products. Established in 2006, QD Laser is headquartered in Kawasaki, Japan.
CREWT Medical Systems, Inc., founded in 2013 and based in Tokyo, Japan, specializes in the manufacture of innovative medical devices. The company is renowned for developing the world's first head-mounted perimeter, which is compatible with standard automated perimeters. This advancement is a result of their expertise in lens design and software engineering, tailored to meet clinical needs. The name "CREWT" stands for "CREation," "Weave," and "Technologies," reflecting the company's mission to create new value by integrating existing technologies. CREWT Medical Systems is dedicated to producing human-centric medical devices aimed at improving quality of vision.
Astroscale Holdings Inc. engages in the development of technologies to remove orbital debris. It offers services, such as end-of-life service by Astroscale (ELSA), a spacecraft retrieval service for satellite operators; and active debris removal (ADR). It also designs and manufactures the lunar dream capsule which gives people a chance to send their names into space. Astroscale Holdings Inc. was founded in 2019 and is headquartered in Tokyo, Japan with additional offices in Harwell, United Kingdom; and Singapore.
Axelspace is a startup company developing businesses in the microsatellite field. Axelspace plans to construct a monitoring platform to cover the entire globe on a daily basis at extremely low cost.
Synspective Inc. provides data by utilizing and integrating data from synthetic aperture radar satellite constellations, big data, and machine learning. It serves urban design, infrastructure, energy, insurance, and finance markets. The company is based in Tokyo, Japan.
TELEXISTENCE inc. provides robotics and cloud data services. It develops a production prototype, MODEL H, that uses remote control technologies utilizing the Telexistence technology, virtual reality (VR), telecommunication, cloud and haptics. The company was founded in 2017 and is based in Minato-ku, Japan.
QD Laser, Inc. is a manufacturer of quantum dot semiconductor lasers and wafers, utilizing GaAs substrate for various applications in communications and industry. The company produces a range of products, including picosecond short-pulse DFB lasers for precision processing, current injection-type lasers in green, yellow-green, and orange for biological sciences, and quantum dot laser arrays for silicon optical circuits. Additionally, it offers broadband gain chips for ophthalmic testing equipment and retinal imaging laser eyewear. QD Laser's technology is applied in areas such as silicon photonics, sensing, and precision machining. The company serves a diverse clientele across telecommunications, manufacturing, medicine, and consumer products. Established in 2006, QD Laser is headquartered in Kawasaki, Japan.
Braizon Therapeutics, Inc. is a Tokyo-based company founded in 2015 that focuses on the research and development of innovative drug delivery systems for the central nervous system. The company aims to advance medicine and life sciences by utilizing cutting-edge technology to enhance the delivery of therapeutics to the brain. This initiative is the result of collaborative research conducted by distinguished professors from the University of Tokyo and Tokyo Medical and Dental University. Braizon Therapeutics is committed to creating new drugs, diagnostics, and life science research reagents that address neurological disorders and improve patient outcomes.
TAGCyx Biotechnologies is a Tokyo-based company founded in 2007 that specializes in the development of novel nucleic acid-based drugs for therapeutic purposes. The company has created the Xenoligo platform, which employs genetic alphabet expansion through unnatural base pairs to produce customized nucleic acids tailored for various therapeutic applications. This proprietary technology enables the discovery of highly functional oligonucleotide drugs, positioning TAGCyx at the forefront of innovative solutions in the biotechnology sector.
AccuRna, Inc. is a biotechnology company established in 2015 and headquartered in Tokyo, Japan. The company focuses on researching and developing nucleic acid-based drugs, employing advanced drug delivery system technologies. AccuRna aims to foster therapeutic innovation by providing effective treatments for refractory diseases that currently lack cures. Through its robust platform, the company aspires to deliver safe and efficient nucleic acid therapies, ultimately striving to offer radical cures to patients suffering from challenging medical conditions worldwide.
Alivas Inc. is a medical company based in Hongo, Tokyo, Japan, focused on developing therapeutic medical devices specifically for refractory constipation. Established in 2017, Alivas operates as a joint venture between Stanford University and the University of Tokyo, collaborating under the Japan Biodesign program to foster innovation in medical device creation. The company's mission is to address unmet needs in the treatment of chronic constipation, aiming to improve patient outcomes through advanced medical technology.
Xenoma Inc. is a spin-off company from Someya Group Organic Transistor Lab in the University of T[okyo and JST/ERATO Someya Bio-Harmonized Electronics Project. Professor Takao Someya have been dealing with Organic Electronics since 2003. His ultrathin and ultraflexible device is harmoniously interface with human bodies by taking advantage of the inherent softness of organic materials. Xenoma is aiming at realizing e-skin, which is a next-generation textile-based wearable electronics as an ideal interface between human and device.
CREWT Medical Systems, Inc., founded in 2013 and based in Tokyo, Japan, specializes in the manufacture of innovative medical devices. The company is renowned for developing the world's first head-mounted perimeter, which is compatible with standard automated perimeters. This advancement is a result of their expertise in lens design and software engineering, tailored to meet clinical needs. The name "CREWT" stands for "CREation," "Weave," and "Technologies," reflecting the company's mission to create new value by integrating existing technologies. CREWT Medical Systems is dedicated to producing human-centric medical devices aimed at improving quality of vision.